Novavax Global Commercial Operations and COVID-19 Vaccine Update

US/Mexico Phase 3 study design Pre-Crossover N = 29,949 Adults R 2:1 novavax Post-Crossover 5 μg antigen + 50 μα Matrix-M 5 μg antigen + 50 μα Matrix-M Placebo Placebo 5 μg 5 μg Placebo Placebo antigen + 50 μg Matrix-M antigen + 50 μα Matrix-M Blinded Crossover 5 μg antigen + 50 μg Matrix-M Day 0 Day 21 Injection 1 Injection 2 Day 0 Injection 1 Day 21 Injection 2 Booster © 2023 NOVAVAX. All rights reserved. 30

View entire presentation